Disappointing outcome of bitopertin treatment for negative symptoms in schizophrenia

June 14, 2017, Elsevier
Functional magnetic resonance imaging (fMRI) and other brain imaging technologies allow for the study of differences in brain activity in people diagnosed with schizophrenia. The image shows two levels of the brain, with areas that were more active in healthy controls than in schizophrenia patients shown in orange, during an fMRI study of working memory. Credit: Kim J, Matthews NL, Park S./PLoS One.

Two new phase III clinical trials investigating the efficacy and safety of bitopertin, a glycine uptake inhibitor considered to be a promising new add-on therapy for treating negative symptoms in schizophrenia, failed to show a benefit of the drug over placebo. The findings throw a wrench in the hopeful efforts to find a treatment for negative symptoms of schizophrenia, which account for some of the most debilitating aspects of the disorder and are associated with poorer outcomes in patients.

The outcomes of the trials were published in a paper in Biological Psychiatry by Dr. Dragana Bugarski-Kirola of Roche Pharmaceuticals in Basal, Switzerland. The randomized, double-blind, parallel-group, placebo-controlled studies were a collaboration between Roche and several research institutions around the world.

"We are back to the drawing board," said Dr. John Krystal, Editor of Biological Psychiatry.

Previous attempts to treat negative symptoms have employed drugs, hormones, and brain stimulation, but none have provided the desired clinical benefit. Research fingering glutamate signaling in negative symptoms has spurred the idea of targeting glutamate receptors, but this approach has failed in large trials. Glycine reuptake inhibitors have been considered a promising alterative to enhance glutamatergic signaling, and a small proof-of-concept study showed that bitopertin, which selectively inhibits glycine transporter type 1 (GlyT-1), reduced negative symptoms in stable patients with .

"GlyT-1 inhibition was one of the most promising approaches to the treatment of schizophrenia," said Krystal. "While it still may be possible to optimize GlyT-1 inhibition as a treatment, these negative results suggest GlyT-1 inhibition is not a broadly effective or optimal therapeutic strategy to enhance NMDA glutamate receptor function in schizophrenia."

The trials were carried out over 201 sites, with each trial including about 600 patients with persistent, predominant negative symptoms of schizophrenia. Patients treated with antipsychotics were administered placebo or bitopertin (5, 10, or 20 mg) for 24 weeks. The doses were chosen to test the minimal effective dose (5 mg) and the dose with a predicted maximal effect (20 mg).

All participants showed some improvement in the negative symptom factor score, but there were no differences between placebo or bitopertin treatment at 24 weeks. No differences were observed in other symptom domains of schizophrenia either. All three doses of bitopertin were well-tolerated and generally safe over the course of the study.

According to Bugarski-Kirola, tackling complex clinical, regulatory and commercial development processes, reliability and quality control was a daunting task when dealing with over 200 study sites across different cultures. "We demonstrated that quality can be accomplished across the sites, but consider a different approach to the design," she said, explaining that rather than treating negative symptom patients as one homogenous target, priority should be given to exploring the usefulness of novel mechanisms in separate negative symptom domains to better define the target population and maximize the chance of success before launching large phase III trials.

Explore further: Disproving hypothesis clears path for research for new treatment options for schizophrenia

More information: Dragana Bugarski-Kirola et al. Bitopertin in Negative Symptoms of Schizophrenia?Results From the Phase III FlashLyte and DayLyte Studies, Biological Psychiatry (2017). DOI: 10.1016/j.biopsych.2016.11.014

Related Stories

Disproving hypothesis clears path for research for new treatment options for schizophrenia

March 10, 2016
Researchers reported results from the first repeated-dose study of a dopamine-1 receptor (D1R) agonist for treating the cognitive and negative symptoms of schizophrenia today in the Journal of Psychopharmacology.

Clinical trial: First treatment for 'emotional flatness' associated with schizophrenia

August 30, 2015
Results of a clinical trial seem to show the first effective treatment for the negative symptoms - withdrawal, lack of emotion, and apathy - associated with schizophrenia. This work is presented at the European College of ...

Study suggests valproate may be effective in patients with variant of COMT gene

September 14, 2016
A drug prescribed to many patients with schizophrenia or bipolar disorder may decrease negative symptoms for people with a certain variant of the COMT gene, suggests a new study from researchers at Columbia University Medical ...

A comparison between quetiapine and aripiprazole for treatment of schizophrenia

July 13, 2016
Schizophrenia is a common cause of incapacity and is ranked as the third-most-disabling illness subsequent to dementia and quadriplegia. Nearly, 75% of persons with schizophrenia have continuing problems with recurrent psychotic ...

New schizophrenia treatments may be effective for subgroup of patients

December 8, 2015
Mounting evidence indicates that disturbances in the brain's glutamate pathway contribute to symptoms of schizophrenia. Thus, the glutamate pathway has become the target of a number of new drug therapies. Findings published ...

New medication significantly decreases involuntary movement

April 7, 2017
Antipsychotic treatment can cause involuntary movements such as lip smacking, tongue protrusions and excessive eye blinking. These movements typically occur after more than 3 months of treatment and are called tardive dyskinesia.

Recommended for you

New approaches in neuroscience show it's not all in your head

February 16, 2018
Our own unique experiences shape how we view the world and respond to the events in our lives. But experience is highly subjective. What's distressing or joyful to one person may be very different to another.

Link between hallucinations and dopamine not such a mystery, finds study

February 16, 2018
Researchers at Columbia University Irving Medical Center (CUIMC) and New York State Psychiatric Institute (NYSPI) found that people with schizophrenia who experience auditory hallucinations tend to hear what they expect, ...

People find comfort listening to the same songs over and over, study finds

February 16, 2018
With the frequency that some people play their favorite song, it's a good thing vinyl records aren't used often because they might wear out.

Ketamine found to reduce bursting in brain area reducing depression quickly

February 15, 2018
A team of researchers at Zhejiang University in China has found that the drug ketamine reduces neuronal bursting in the lateral habenula (LHb) brain region, reducing symptoms of depression in rodent models. In their paper ...

What predicts the quality of children's friendships? Study shows cognition, emotion together play

February 15, 2018
Whether children think their peers' intentions are benign or hostile, and how those children experience and express their own emotions, may influence the quality of their friendships, according to a new study from the University ...

Evidence shows pets can help people with mental health problems

February 15, 2018
The study of 17 research papers by academics at the Universities of Manchester, Southampton and Liverpool, concludes that pets can help people manage their long-term mental health conditions.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.